It's the kind of mirror image Corgentech Inc. didn't want: Only a few months after reporting a Phase III failure for edifoligide (E2F Decoy), its partnered product with Bristol-Myers Squibb Co., the investigational drug again fell short in another Phase III study. (BioWorld Today)